US5658894A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for inhibiting restenosis
Assignee: University of Pennsylvania
•
Filing: 1994-11-23
•
Granted: 1997-08-19
•
Expires: 2014-11-23
Abstract
Abstract Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.
Inventors
- 👤 Paul B. Weisz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/716; A61K31/724; B; B82; B82Y; B82Y5/00; A61K31/737; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/28; A61L26/00; A61L26/0009; A61L26/0023; A61L27/00; A61L27/14; A61L27/20; A61L27/28; A61L27/34; A61L27/50; A61L27/54; A61L33/00; A61L33/0005; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; C07K14/503; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/232; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/80; A61L2300/802; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/812; Y10S530/813; Y10S530/815; Y10S530/817
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
61 words
A composition for promoting or inhibiting the growth of living tissue in mammals comprising a polyanionic cyclodextrin derivative in polymeric form having a body temperature solubility of less than about 15 grams/100 ml of distilled water and a physiologically acceptable carrier for the cyclodextrin derivative, said polyanionic cyclodextrin derivative in polymeric form being effective for improving the healing of wounded tissue.
Claim 2
Dependent Claim
61 words
A composition for promoting or inhibiting the growth of living tissue in mammals comprising a polyanionic cyclodextrin derivative in polymeric form having a body temperature solubility of less than about 15 grams/100 ml of distilled water and a physiologically acceptable carrier for the cyclodextrin derivative, said polyanionic cyclodextrin derivative in polymeric form being effective for improving the healing of wounded tissue.
Claim 3
Dependent Claim
21 words
The composition of claim 1 wherein said cyclodextrin derivative has on average at least about 1.4 anionic substituents per sugar unit.
Claim 4
Dependent Claim
27 words
The composition of claim 2 wherein the monomer units of said cyclodextrin derivative have on average from about 1.4 to about 3 anionic substituents per sugar unit.
Claim 5
Dependent Claim
23 words
The composition of claim 3 wherein said cyclodextrin derivative has on average from about 1.4 to about 2.5 anionic substituents per sugar unit.
Claim 6
Dependent Claim
83 words
The composition of claim 1 wherein the monomer units of said cyclodextrin derivative in polymeric form comprise compounds of the formula: ##STR2## wherein at least two of said R groups per monomeric unit are selected from the group consisting of sulfate, phosphate, sulfonate and nitrate, and the remainder of said R groups, when present, are nonanionic groups selected from the group consisting of H, alkyl, aryl, ester, ether, thioester, thioether and --COOH; and n is an integer from about 6 to about 12.
Claim 7
Dependent Claim
13 words
The composition of claim 5 which further comprises a heparin binding growth factor.
Claim 8
Dependent Claim
15 words
The composition of claim 6 wherein the heparin binding growth factor is fibroblast growth factor.
Claim 9
Dependent Claim
20 words
The composition of claim 1 which comprises cyclodextrin monomers having on average at least about 10 anionic substituents per monomer.
Claim 10
Dependent Claim
21 words
The composition of claim 8 wherein said monomers have on average from about 10 to about 24 anionic substituents per monomer.
Claim 11
Dependent Claim
18 words
The composition of claim 1 wherein said cyclodextrin derivative is solid particulate dispersed or suspended in said carrier.
Claim 12
Dependent Claim
18 words
The composition of claim 1 wherein said cyclodextrin derivative comprises a salt of polyanionic alpha-, beta- or gamma-cyclodextrin.
Claim 13
Dependent Claim
34 words
The composition of Claim 11 wherein the cationic constituents of said salt are selected from the group consisting of Mg, Al, Ca, La, Ce, Na, Ba and combinations of two or more of these.
Claim 14
Dependent Claim
16 words
The composition of claim 1 wherein said derivative is substantially insoluble in water at body temperature.
Claim 15
Dependent Claim
23 words
The composition of claim 1 wherein at least a portion of said cyclodextrin derivative is solid particulate dispersed or suspended in said carrier.
References Cited (Backward Citations)
US2923704A
Cited
US3420788A
Cited
JPS5036422A
Cited
JPS50140476A
Cited
US4020160A
Cited
US4066829A
Cited
US4247535A
Cited
US4258180A
Cited
US4383992A
Cited
JPS58171404A
Cited
EP0121777A2
Cited
US4582900A
Cited
WO1985002767A1
Cited
US4596795A
Cited
US4727064A
Cited
EP0188821A2
Cited
EP0193850A2
Cited
US4764604A
Cited
US4764604B1
Cited
JPS62123196A
Cited
WO1987005808A1
Cited
US4840941A
Cited
US4834985A
Cited
US4912093A
Cited
JPS63122701A
Cited
US4869904A
Cited
US4929577A
Cited
DE3819498A1
Cited
US4877778A
Cited
US4774329A
Cited
US4877774A
Cited
US4929602A
Cited
US5019562A
Cited
WO1989006536A1
Cited
EP0325199A2
Cited
US5135919A
Cited
JPH01315401A
Cited
US4902788A
Cited
US5075432A
Cited
US5183809A
Cited
EP0447171A2
Cited
US5164379A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-08-18 | 2001-02-17 | 2001-08-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-08-18 | 2005-02-17 | 2005-08-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-08-18 | 2009-02-17 | 2009-08-19 | $7700.00 | Window Closed / Lapsed |